Castle IRB meets once a week (Wednesdays) for convened Board Meetings. Ad hoc meetings can be scheduled as needed with the IRB team. Please see submission deadline information below.

Expedited Reviews, Exempt Reviews, Human Subjects Research Determinations, and Generic Material Reviews have no submission deadlines and are reviewed upon receipt.

Full Board Review
  • Submissions must be received the Monday before the following week’s Wednesday Board Meeting.
  • Turnaround time: 10 business days or less from study submission to IRB review and Determination Letter distribution
Expedited Review (if applicable)
  • No submission deadlines
  • Main study review turnaround time: typically 5 business days or less from study submission to IRB review and Determination Letter distribution
  • PI/site (multi-investigator projects): 2-3 days from PI/site submission following main study review
Ongoing submissions following Initial Review
  • If requires Full Board: turnaround time and submission deadline as noted above
  • If can be reviewed via Expedited Review: turnaround time as noted above
Exempt Review (if applicable)
  • No submission deadlines
  • Turnaround time: typically 4 business days or less from submission to IRB review and Determination Letter distribution
Human Subjects Research Determinations/Generic Materials
  • No submission deadlines
  • Turnaround time: typically 2-3 business days from submission to IRB review and Determination Letter distribution

Contact Us Today

Mission Statement

The mission of Castle IRB is to protect the rights and welfare of human participants in gene and cell therapy clinical trials while providing efficient, compliant IRB review of research. Using our portfolio of expertise, we strive to be the leading IRB partner in advancing safe, ethical and compliant gene and cell therapy clinical trials to accelerate the next evolution in advanced therapies.